Small Molecule Inhibitors Targeting Acidic Tumor Microenvironment Show Promise Despite Clinical Translation Hurdles

The acidic tumor microenvironment (TME), characterized by a pH of 6.5-6.9, is a critical hallmark of solid tumors, primarily sustained by the Warburg effect and various pH regulators. These regulators include monocarboxylate transporters 1 and 4 (MCT1/4), Na+/H+ exchanger 1 (NHE1), vacuolar ATPase (v-ATPase), and carbonic anhydrases IX and XII (CAIX/XII). This hostile environment significantly contributes to tumor invasion, immune evasion, and resistance to conventional therapies, presenting a major obstacle in cancer treatment. Targeting these specific pH-regulating pathways offers a promising strategy to overcome therapeutic resistance and improve patient outcomes.

This comprehensive review article systematically analyzed recent advancements in small molecule inhibitors designed to target the acidic tumor microenvironment. The authors focused on the structural design, structure-activity relationships (SAR), and biological activity of these inhibitors. They also summarized their progress in preclinical studies and clinical trials. Additionally, the review explored various acid-targeted delivery strategies, such as pH-responsive prodrugs and pHLIP peptides, which aim to enhance drug specificity and efficacy within the tumor. The overarching goal was to identify opportunities and challenges in manipulating acid-base regulation for novel antitumor drug development.

The review identified significant progress in the development of small molecule inhibitors targeting key pH regulators within the acidic TME, including MCT1/4, NHE1, v-ATPase, and CAIX/XII. These inhibitors have demonstrated promising potential in molecular design and preclinical studies by disrupting the tumor's ability to maintain an acidic environment, thereby hindering tumor invasion, immune evasion, and therapy resistance. The article detailed the mechanisms of action for several compounds, highlighting their ability to selectively modulate pH. Furthermore, it underscored the emergence of innovative acid-targeted delivery strategies, such as pH-responsive prodrugs and pHLIP peptides, which aim to improve drug accumulation and efficacy specifically within acidic tumor regions. However, the review also emphasized persistent challenges in translating these findings to practical applications.

Despite preclinical promise, inhibitors face hurdles like metabolic compensation, insufficient target selectivity, and difficulties in achieving successful clinical translation.